Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SOT201: <i>cis</i>-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors.

Expert opinion on investigational drugs·2026

Same author

[Late complications after atrial fibrillation ablation : Diagnosis and management].

Herzschrittmachertherapie & Elektrophysiologie·2026

Same author

CD64-Targeted Polymer-Drug Conjugates Exploit Cathepsin K-Dependent Payload Release for Selective Elimination of Immunosuppressive Macrophages.

Molecular pharmaceutics·2026

Same author

NKG2A inhibition promotes NK cell-CD8<sup>+</sup> T cell interactions to improve anticancer immunity in ovarian carcinoma.

Nature communications·2026

Same author

Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the <i>in vivo</i> persistence of regulatory T cells.

Frontiers in immunology·2026

Same author

Aluminum Genotoxicity in Plants, Mammals, and Unicellular Eukaryotes: The Underlying Mechanisms.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Mar 31, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy.

Petra Votavova, Jakub Tomala, Vladimir Subr

Journal of Biomedical Nanotechnology

|October 22, 2015

Summary

Researchers improved Interleukin-2 (IL-2) immunotherapy by conjugating it with a polymer carrier (HPMA). This IL-2-poly(HPMA) conjugate demonstrated enhanced in vivo activity and extended half-life, offering a promising approach for cancer treatment.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

Related Experiment Videos

Last Updated: Mar 31, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

Area of Science:

Immunology
Biotechnology
Polymer Chemistry

Background:

Interleukin-2 (IL-2) is a potent immune-stimulating cytokine crucial for T and NK cell activity, making it a candidate for immunotherapy.
High-dose IL-2 therapy is limited by a very short in vivo half-life and significant toxicities.
Developing strategies to enhance IL-2's therapeutic efficacy and reduce side effects is critical.

Purpose of the Study:

To improve the pharmacokinetic properties and in vivo potency of Interleukin-2 (IL-2) for enhanced immunotherapy.
To synthesize and characterize an IL-2 conjugate using a synthetic polymeric carrier, N-(2-hydroxypropyl)methacrylamide (HPMA).

Main Methods:

Covalent conjugation of a synthetic semitelechelic poly(HPMA) carrier to Interleukin-2 (IL-2).
Characterization of the resulting IL-2-poly(HPMA) conjugate, determining the average number of polymer chains per IL-2 molecule.
In vitro and in vivo evaluation of the conjugate's biological activity, immune cell expansion, and pharmacokinetic profile compared to native IL-2.

Main Results:

The synthesized IL-2-poly(HPMA) conjugate exhibited lower biologic activity in vitro compared to native IL-2.
In vivo, the IL-2-poly(HPMA) conjugate demonstrated significantly higher activity, promoting the expansion of memory CD8+ T, NK, NKT, γδT, and Treg cells.
The conjugate markedly enhanced CD8+ T cell peptide-based vaccination efficacy and exhibited a substantially longer half-life in circulation (approximately 4 hours vs. 5 minutes for IL-2).

Conclusions:

Modification of IL-2 with poly(HPMA) chains dramatically improves its in vivo potency and pharmacokinetic features.
This polymer-protein modification represents a novel strategy to enhance IL-2's therapeutic potential in immunotherapy.
This study provides the first proof-of-concept for using polymer modification of IL-2 to achieve more pronounced biological activity and improved therapeutic outcomes.